Dihexa
A synthetic hexapeptide derived from angiotensin IV that potently promotes synaptogenesis — the formation of new neuronal connections. Approximately 7 orders of magnitude more potent than BDNF in hippocampal synaptogenesis assays. Human data is extremely limited.
Reviewed & fact-checked by
BiohackingHub Research TeamEditorial Research Team · Last updated: March 26, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Is Dihexa
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derived from angiotensin IV, developed by researchers at Washington State University. It acts as an agonist at the HGF/c-Met signalling pathway — hepatocyte growth factor and its receptor, which plays a critical role in neuronal survival and synaptogenesis.
The compound gained its reputation from a 2011 paper by McCoy et al. showing Dihexa was approximately 7 orders of magnitude more potent than BDNF in promoting new synaptic connections in hippocampal tissue preparations. [] This figure is often misrepresented in the nootropic community — it refers to a specific in vitro synaptogenesis assay, not general cognitive enhancement.
The Evidence Landscape — Honest Assessment
Animal data (strong): Dihexa reversed cognitive deficits in Alzheimer's mouse models, improved spatial memory in aged rats, and promoted synaptogenesis across multiple hippocampal assays. The HGF/c-Met mechanistic pathway is well-characterised.
Human data (nearly absent): As of 2026, there are no published randomised controlled trials in humans. All human "evidence" is anecdotal — community reports from nootropic forums and self-experimenters. This is a critical distinction.
Important caveat: The synaptogenic activity that makes Dihexa interesting could theoretically be problematic in the context of cancer, as HGF/c-Met signalling promotes angiogenesis. This is a theoretical concern, not a documented clinical risk, but warrants caution.
Intranasal vs. Oral Administration
The blood-brain barrier presents a significant obstacle for oral Dihexa. Intranasal administration bypasses this barrier via the olfactory epithelium pathway — most experienced users prefer this route. Oral bioavailability is poorly characterised.
Practical Usage Notes
Start extremely low (1–2mg intranasal) to assess individual response. Report from experienced users suggest effects may be subtle initially and accumulate over 2–4 weeks of cycling. The "God molecule" marketing should be treated with scepticism — this is a promising research compound with extraordinary animal data and essentially no human clinical validation.
Stacking Interactions
How Dihexa interacts with other compounds
Lion's Mane 500–1000mg daily; dihexa in cycles. The NGF + synaptogenesis combination addresses neuroplasticity from two angles.
300–600mg Alpha-GPC with Dihexa cycles. Essential for supporting new synaptic connections.
Stack with caution — combined neuroplasticity may cause cognitive overload. Start with lower doses of each.
Safety Profile — Tier B
Generally safe — moderate evidence
Contraindications
- ●Active cancer (synaptogenic activity may theoretically promote tumour angiogenesis)
- ●Pregnancy or breastfeeding (no safety data)
- ●Children and adolescents (developing nervous system)
Side Effects
- ●Limited human safety data — most experience derived from animal models
- ●Reported: headache, vivid dreams, mild anxiety in some users
- ●Potential vasopressor activity (blood pressure elevation) via AT4 receptor
- ●Unknown long-term effects in humans